All In Biotech

NDA 020554 · Leo Pharma As

Dovonex

Calcipotriene · Topical · Vitamin D Analog

Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jul 22, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

167

41 Phase 3, 8 recruiting

FAERS reports

3,398

1,388 serious, 69 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 6, 2026.

INDICATIONS AND USAGE Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 22, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
  • DOVONEX · CALCIPOTRIENE 0.005% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Calcipotriene" as an intervention, any sponsor and status, largest first.

All 167 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective832
  • psoriasis718
  • diarrhoea210
  • arthralgia200
  • rash187
  • nausea186
  • pain182
  • pruritus177
  • off label use173
  • headache169
  • product use in unapproved indication156
  • therapeutic product effect incomplete144

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200510
200612
200716
200831
200921
201024
20116
201224
201349
201452
2015130
2016140
2017164
2018164
2019235
2020216
2021225
2022215
2023942
2024251
2025263
2026202

Recalls

1 FDA enforcement reports for this application.

  • Jan 19, 2017 · Class II · Terminated

    Incorrect/Undeclared excipients: inadvertent omission of a drug excipient from the the Authorized Generic label and also a warning regarding contact dermatitis from the brand product labeling not being incorporated into...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 86 on PubMed

Sponsor: Leo Pharma As

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.